Covered recipient · General Payments record
SIBY G AYALLOORE
Allopathic & Osteopathic Physicians Internal Medicine Advanced Heart Failure and Transplant Cardiology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$3,764.46
140 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,975.19 | 137 |
| Travel and Lodging | $781.37 | 2 |
| Education | $7.90 | 1 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Merck Sharp & Dohme Corporation | $970.37 | 6 |
| PFIZER INC. | $555.46 | 43 |
| Abbott Laboratories | $501.61 | 10 |
| ABIOMED | $369.05 | 5 |
| Boston Scientific Corporation | $287.54 | 12 |
| Janssen Pharmaceuticals, Inc | $177.30 | 17 |
| United Therapeutics Corporation | $129.30 | 3 |
| ShockWave Medical, Inc | $126.91 | 1 |
| Cook Medical LLC | $123.82 | 1 |
| Novartis Pharmaceuticals Corporation | $120.57 | 14 |
| Tactile Systems Technology Inc | $81.08 | 5 |
| E.R. Squibb & Sons, L.L.C. | $68.91 | 6 |
| Gilead Sciences, Inc. | $54.26 | 4 |
| Medtronic Vascular, Inc. | $52.11 | 3 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $43.18 | 3 |
| Amgen Inc. | $29.91 | 2 |
| Lundbeck LLC | $21.91 | 1 |
| Chiesi USA, Inc. | $14.44 | 1 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $13.07 | 1 |
| Regeneron Healthcare Solutions, Inc. | $12.40 | 1 |
| AstraZeneca Pharmaceuticals LP | $11.26 | 1 |
Page 3 of 3; records 101–140 of 140 matching records. This page contains 40 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SIBY G AYALLOORE
NPI 1891985081 · CMS profile ID 267277
Allopathic & Osteopathic Physicians / Internal Medicine / Advanced Heart Failure and Transplant Cardiology
OPELOUSAS, LA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–140 of 140 matching records. This page contains 40 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1891985081?year=2019&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SIBY G AYALLOORE, NPI 1891985081, CMS profile ID 267277. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–140 of 140 matching records. This page contains 40 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1891985081?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). SIBY G AYALLOORE, NPI 1891985081, CMS profile ID 267277. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–140 of 140 matching records. This page contains 40 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1891985081?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- SIBY G AYALLOORE, NPI 1891985081, CMS profile ID 267277, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–140 of 140 matching records. This page contains 40 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1891985081?year=2019&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
140 matching records · $3,764.46 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–140 of 140.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Boston Scientific Corporation | $9.73 | 04/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709054963 | CMS |
| Abbott Laboratories | $10.06 | 04/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 664566209 | CMS |
| E.R. Squibb & Sons, L.L.C. | $11.63 | 04/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651335087 | CMS |
| Abbott Laboratories | $3.62 | 03/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 664604497 | CMS |
| Janssen Pharmaceuticals, Inc | $19.86 | 03/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658281507 | CMS |
| Janssen Pharmaceuticals, Inc | $4.24 | 03/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658281505 | CMS |
| Janssen Pharmaceuticals, Inc | $4.07 | 03/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658281503 | CMS |
| PFIZER INC. | $14.12 | 03/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671906389 | CMS |
| PFIZER INC. | $0.82 | 03/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672012725 | CMS |
| PFIZER INC. | $0.34 | 03/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672042099 | CMS |
| Novartis Pharmaceuticals Corporation | $2.79 | 03/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659158927 | CMS |
| Boston Scientific Corporation | $17.77 | 03/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 663006833 | CMS |
| PFIZER INC. | $16.13 | 03/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671906623 | CMS |
| Novartis Pharmaceuticals Corporation | $17.67 | 03/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659158892 | CMS |
| ABIOMED | $122.27 | 03/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 676722217 | CMS |
| Janssen Pharmaceuticals, Inc | $10.47 | 03/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658281501 | CMS |
| Merck Sharp & Dohme Corporation | $48.00 | 02/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695802479 | CMS |
| Merck Sharp & Dohme Corporation | $20.00 | 02/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695802725 | CMS |
| Merck Sharp & Dohme Corporation | $30.00 | 02/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695802729 | CMS |
| Merck Sharp & Dohme Corporation | $568.73 | 02/27/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695802481 | CMS |
| Merck Sharp & Dohme Corporation | $91.00 | 02/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695802483 | CMS |
| Merck Sharp & Dohme Corporation | $212.64 | 02/27/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695802727 | CMS |
| E.R. Squibb & Sons, L.L.C. | $11.03 | 02/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651335085 | CMS |
| PFIZER INC. | $19.52 | 02/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671897393 | CMS |
| Boston Scientific Corporation | $16.00 | 02/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 663006805 | CMS |
| Janssen Pharmaceuticals, Inc | $12.02 | 02/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658281499 | CMS |
| Janssen Pharmaceuticals, Inc | $1.97 | 02/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658281497 | CMS |
| Novartis Pharmaceuticals Corporation | $2.97 | 02/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659158913 | CMS |
| Novartis Pharmaceuticals Corporation | $8.87 | 02/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659158919 | CMS |
| Gilead Sciences, Inc. | $13.20 | 02/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681475333 | CMS |
| PFIZER INC. | $18.39 | 02/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671890987 | CMS |
| PFIZER INC. | $4.10 | 02/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672030161 | CMS |
| Gilead Sciences, Inc. | $14.69 | 02/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681475331 | CMS |
| Novartis Pharmaceuticals Corporation | $4.52 | 02/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659158907 | CMS |
| Janssen Pharmaceuticals, Inc | $13.80 | 01/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658281495 | CMS |
| Boston Scientific Corporation | $20.76 | 01/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 663006843 | CMS |
| PFIZER INC. | $16.77 | 01/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671847431 | CMS |
| Janssen Pharmaceuticals, Inc | $11.67 | 01/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658281493 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $13.97 | 01/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700400029 | CMS |
| PFIZER INC. | $15.17 | 01/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671847735 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $235,389.33 | 17 |
| PY2024 | Principal investigator | $206,092.30 | 11 |
| PY2023 | Principal investigator | $217,398.65 | 11 |
| PY2022 | Principal investigator | $92,594.24 | 8 |
| PY2021 | Principal investigator | $49,152.74 | 9 |
| PY2020 | Principal investigator | $38,009.00 | 5 |
| PY2019 | Principal investigator | $35,225.00 | 12 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
17 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $5,465.01 | 12/31/2025 | Non-covered Recipient Entity Cardiovascular Institute of the South | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction | No dispute reported | 06/30/2026 | 1232920089 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $86.68 | 12/31/2025 | Non-covered Recipient Entity CARDIOVASCULAR INSTITUTE OF THE SOUTH OPELOUSAS | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) | No dispute reported | 06/30/2026 | 1190307737 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $12,551.00 | 12/03/2025 | Non-covered Recipient Entity Cardiovascular Institute of the South (CIS) - Opelousas | A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | No dispute reported | 06/30/2026 | 1215508809 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,598.00 | 12/03/2025 | Non-covered Recipient Entity Cardiovascular Institute of the South (CIS) - Opelousas | A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | No dispute reported | 06/30/2026 | 1215508813 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $20.16 | 11/15/2025 | Non-covered Recipient Entity CARDIOVASCULAR INSTITUTE OF THE SOUTH OPELOUSAS | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190307743 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $112.58 | 10/30/2025 | Non-covered Recipient Entity CARDIOVASCULAR INSTITUTE OF THE SOUTH OPELOUSAS | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi | No dispute reported | 06/30/2026 | 1190307747 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $8,500.00 | 10/23/2025 | Non-covered Recipient Entity CIS CLINICAL RESEARCH CORP | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190309088 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $133.67 | 10/09/2025 | Non-covered Recipient Entity CARDIOVASCULAR INSTITUTE OF THE SOUTH OPELOUSAS | A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD | No dispute reported | 06/30/2026 | 1190307613 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $18,096.71 | 06/30/2025 | Non-covered Recipient Entity CARDIOVASCULAR INSTITUTE OF THE SOUTH OPELOUSAS | A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD | No dispute reported | 06/30/2026 | 1190307615 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $3,770.70 | 03/27/2025 | Non-covered Recipient Entity CIS CLINICAL RESEARCH CORP | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190299183 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,120.00 | 03/25/2025 | Non-covered Recipient Entity CIS CLINICAL RESEARCH CORP | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190299190 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $10,986.42 | 02/28/2025 | Non-covered Recipient Entity CARDIOVASCULAR INSTITUTE OF THE SOUTH OPELOUSAS | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi | No dispute reported | 06/30/2026 | 1190307611 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $46,612.85 | 02/04/2025 | Non-covered Recipient Entity CIS CLINICAL RESEARCH CORP | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi | No dispute reported | 06/30/2026 | 1190299194 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $18,065.70 | 01/30/2025 | Non-covered Recipient Entity CIS CLINICAL RESEARCH CORP | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) | No dispute reported | 06/30/2026 | 1190298830 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $30,185.74 | 01/27/2025 | Non-covered Recipient Entity CARDIOVASCULAR INSTITUTE OF THE SOUTH OPELOUSAS | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190307741 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,424.39 | 01/15/2025 | Non-covered Recipient Entity CARDIOVASCULAR INSTITUTE OF THE SOUTH OPELOUSAS | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190307745 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $74,659.72 | 01/13/2025 | Non-covered Recipient Entity CARDIOVASCULAR INSTITUTE OF THE SOUTH OPELOUSAS | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) | No dispute reported | 06/30/2026 | 1190307739 |